Brookline upgraded Rein Therapeutics (RNTX) to Buy from Hold with a $6 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNTX:
- Rein Therapeutics Resumes Phase 2 Trial for LTI-03
- Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03
- Rein Therapeutics Secures Third Pre-Paid Advance
- Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03
- Rein Therapeutics initiated with a Buy at H.C. Wainwright